Interviews

From CRDMO to BioInnovation Venture Accelerator: A Conversation with XL Lin, CEO of Esco Aster

Esco Aster has grown beyond a CRDMO, adding on a vertically integrated bioinnovation venture accelerator, offering “idea-to-exit” support that spans consultancy, CMC development, manufacturing, testing, clinical development, business development, and strategic investment. CEO XL Lin shares how this evolution came about, what sets Esco Aster’s Metamorphosis program apart, and what advice he has for Singapore’s next generation of bioentrepreneurs.

By Biotech Connection Singapore, ago

Mitigating COVID-19 impact on the Construction Industry

COVID-19 has greatly affected the construction industry by causing employee absenteeism, a problem which leads to project delays and loss of revenue for many companies. Hear about how Genscript’s new SARS-CoV-2 cPass™ serology test for neutralising antibodies has been helping construction workers make informed decisions to take vaccine boosters and stay protected.

By Biotech Connection Singapore, ago

Life Pre- and Post-IPO: The journey of iX Biopharma and ASLAN Pharmaceuticals

In this new and exciting article we capture the journey of two public-listed company – iX Biopharma and ASLAN Pharmaceuticals, listed on SGX and Nasdaq respectively in a series of questions and answers. Hear what Ms Eva Tan, Director of Corporate and Commercial Strategy at iX Biopharma and Dr. Carl Firth, founder and CEO of ASLAN Pharmaceuticals have to say about their journey going public, and how start-ups can undertake this path successfully. By Shainan Hora

By Biotech Connection Singapore, ago